Literature DB >> 15495241

5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells.

Motoyuki Suzuki1, Akira Harashima, Ayumi Okochi, Mayuko Yamamoto, Shuji Nakamura, Ryuichi Motoda, Fumiyuki Yamasaki, Kunzo Orita.   

Abstract

DNA methylation plays important roles in a wide range of biological phenomena, especially in the embryonic development and tumorigenesis. However, correlations between differentiation and DNA methylation have not been clarified well in each differentiation system. In this study, we focused our attention on regulatory roles of DNA methylation in normal hematopoietic differentiation using a demethylating reagent, 5-azacytidine (5-AzaC). As a source of hematopoietic progenitor cells, we used CD34(+) cells prepared from human umbilical cord blood and examined the effects of 5-AzaC on the colony-forming activity and the long-term culture-initiating (LTC-IC) activity of these cells. 5-AzaC treatment increased LTC-IC frequency 1.57- to 2.50-fold as compared to the nontreated control. In parallel to this, immunoblotting analysis showed that the intensity of overall DNA methylation decreased after 5-AzaC treatment. These results indicated the involvement of DNA methylation and demethylation in controlling immaturity of hematopoietic progenitor cells and the usefulness of 5-AzaC for regulating this immaturity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15495241     DOI: 10.1002/ajh.20178

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus.

Authors:  Zhenbo Hu; Soledad Negrotto; Xiaorong Gu; Reda Mahfouz; Kwok Peng Ng; Quteba Ebrahem; Edward Copelan; Harinder Singh; Jaroslaw P Maciejewski; Yogen Saunthararajah
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

Review 2.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.

Authors:  Yogen Saunthararajah; Pierre Triozzi; Brian Rini; Arun Singh; Tomas Radivoyevitch; Mikkael Sekeres; Anjali Advani; Ramon Tiu; Frederic Reu; Matt Kalaycio; Ed Copelan; Eric Hsi; Alan Lichtin; Brian Bolwell
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

3.  p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.

Authors:  K P Ng; Q Ebrahem; S Negrotto; R Z Mahfouz; K A Link; Z Hu; X Gu; A Advani; M Kalaycio; R Sobecks; M Sekeres; E Copelan; T Radivoyevitch; J Maciejewski; J C Mulloy; Y Saunthararajah
Journal:  Leukemia       Date:  2011-06-24       Impact factor: 11.528

4.  Noncytotoxic differentiation treatment of renal cell cancer.

Authors:  Soledad Negrotto; Zhenbo Hu; Oscar Alcazar; Kwok Peng Ng; Pierre Triozzi; Daniel Lindner; Brian Rini; Yogen Saunthararajah
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

5.  CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors.

Authors:  S Negrotto; K P Ng; A M Jankowska; J Bodo; B Gopalan; K Guinta; J C Mulloy; E Hsi; J Maciejewski; Y Saunthararajah
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

Review 6.  Cord blood in regenerative medicine: do we need immune suppression?

Authors:  Neil H Riordan; Kyle Chan; Annette M Marleau; Thomas E Ichim
Journal:  J Transl Med       Date:  2007-01-30       Impact factor: 5.531

7.  Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.

Authors:  Kongfei Li; Chao Hu; Chen Mei; Zhigang Ren; Juan Carlos Vera; Zhengping Zhuang; Jie Jin; Hongyan Tong
Journal:  J Transl Med       Date:  2014-06-12       Impact factor: 5.531

8.  Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.

Authors:  Nicholas B Berry; Sharmila A Bapat
Journal:  J Ovarian Res       Date:  2008-11-24       Impact factor: 4.234

9.  Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.

Authors:  Seunghoon Han; Yoo-Jin Kim; Jongtae Lee; Sangil Jeon; Taegon Hong; Gab-Jin Park; Jae-Ho Yoon; Seung-Ah Yahng; Seung-Hwan Shin; Sung-Eun Lee; Ki-Seong Eom; Hee-Je Kim; Chang-Ki Min; Seok Lee; Dong-Seok Yim
Journal:  J Hematol Oncol       Date:  2015-10-23       Impact factor: 17.388

10.  Hematopoietic stem and progenitor cells acquire distinct DNA-hypermethylation during in vitro culture.

Authors:  Carola Ingrid Weidner; Thomas Walenda; Qiong Lin; Monika Martina Wölfler; Bernd Denecke; Ivan Gesteira Costa; Martin Zenke; Wolfgang Wagner
Journal:  Sci Rep       Date:  2013-11-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.